IL5 and asthma: Dupilumab (Dupixent®) is the first biologic therapy approved for treating uncontrolled severe asthma with type 2 inflammation, including allergic (anti-immunoglobulin [Ig]-E) and eosinophilic (anti-interleukin [IL]-5) phenotypes [6].